Insperity (NSP) is back on investor radars after management highlighted continued progress with its Insperity HRScale solution, which blends Workday software with the company’s full-service professional employer organization offering.
The update matters because it links Insperity’s product rollout with fresh third party research. 3Sixty Insights reports that only 13% of employers fully use most Human Capital Management features, while 49% say they would pay more for stronger provider support.
Recent trading has been choppy, with Insperity’s share price down 4.1% over the past week and 8.5% over the past month. However, a 15.6% 90-day share price return and 24.0% year-to-date gain point to momentum that contrasts with a muted 4.7% 1-year total shareholder return and significant 3- and 5-year total shareholder return declines. The HRScale update now sits squarely in the middle of that changing risk and opportunity story.
Compare Insperity’s HRScale push with peers modernizing HR and payroll by scanning the hand picked list of solid balance sheet and fundamentals (24 results) for ideas beyond a single ticker.
Insperity shares have swung from long term underperformance to a sharp 90 day rebound, just as HRScale gains attention. Does that setup still tilt the risk reward toward buyers, or has the easy upside already been taken?
Insperity last closed at $47.90, while the most followed narrative pegs fair value closer to $51.75. The recent pullback is therefore being weighed against a modest valuation gap that depends heavily on the HRScale rollout and margin repair story.
The upcoming launch of Insperity HRScale, a joint solution with Workday, targets a broader and more lucrative mid-market segment, leveraging both advanced HR technology and comprehensive services; this is expected to drive higher revenue growth and improved operating leverage as premium pricing and larger average client size become possible.
See why 6 investors see Insperity as 7% undervalued.
Result: Fair Value of $51.75 (UNDERVALUED)
Still, the Insperity story hinges on sensitive pressure points, including trends in healthcare costs and execution on the multiyear Workday partnership investment.
Find out about the key risks to this Insperity narrative.
Mixed signals around Insperity can feel either confusing or like an opening. Act quickly, examine both sides of the story, then weigh the 3 key rewards and 1 important warning sign.
If Insperity has you rethinking your watchlist, do not stop at a single HR specialist. Use structured stock lists to pressure test your thesis and spot fresh opportunities.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com